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Abstract Successful clinical outcomes from transplantation
of hematopoietic stem cells (HSCs) depend upon efficient
HSC homing to bone marrow (BM), subsequent engraftment,
and, finally, BM repopulation. Homing of intravenously ad-
ministered HSCs from peripheral blood (PB) through the cir-
culation to the BM stem cell niches, which is the first critical
step that precedes their engraftment, is enforced by chemotac-
tic factors released in the BM microenvironment that
chemoattract HSCs. These chemotactic factors include α-
chemokine stromal-derived factor 1 (SDF-1), the bioactive
phosphosphingolipids sphingosine-1-phosphate (S1P) and
ceramid-1-phosphate (C1P), and the extracellular nucleotides
ATP and UTP. Stem cells may also respond to a Ca2+ or H+
gradient by employing calcium- or proton-sensing receptors,
respectively. In this review, we will present emerging strate-
gies based on ex vivo manipulation of graft HSCs that are
aimed at enhancing the responsiveness of HSCs to BM-
secreted chemoattractants and/or promoting HSC adhesion
and seeding efficiency in the BM microenvironment.
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Introduction
After intravenous infusion, hematopoietic stem/progenitor
cells (HSPCs) home through the circulation from peripheral
blood (PB) to the bone marrow (BM) stem cell niches in
response to chemoattractants secreted in the BM microenvi-
ronment, and this process precedes their subsequent engraft-
ment and repopulation of the recipient’s hematopoietic organs
[1–3]. It is well known that hematopoietic recovery after trans-
plantation of HSPCs and the final clinical outcome depend on
the number and quality of HSPCs present in a graft, which can
be estimated in humans by calculating the number of mono-
nuclear cells that express the CD34 antigen. Based on this
method, it has been determined that, for transplantation of
umbilical cord blood (UCB) with ≤2 human leucocyte antigen
(HLA) disparities, the patient has to be infused with ≥2×105
UCB-derived CD34+ cells/kg body weight [4]. When adult
sources of HSPCs are employed (e.g., mobilized autologous
PB), 2.5×106 CD34+ cells/kg body weight is considered a
sufficient dose for successful stem cell autotransplant; howev-
er, a dose of 5.0×106 CD34+ cells/kg is considered preferable
for achieving early engraftment [5].
These numbers point to the fact that hematopoietic recon-
stitution and recovery of normal PB counts after hematopoi-
etic transplantation depends on the number of infused HSPCs.
On the other hand, it is well known that not all HSPCs infused
into the circulation find their way to the stem cell niches in
BM, and the majority is trapped in different non-
hematopoietic locations in various organs. Therefore, it is im-
portant to develop more efficient strategies that improve the
seeding efficiency of HSPCs by transplanting them directly to
the BM microenvironment [6, 7]. This is a very important
issue, in particular when the number of HSPCs in the graft is
low, as seen, for example, in adult recipients of UCB when
there are low numbers of CD34+ cells harvested from BM, or
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as a result of poor HSPC donor mobilization [6–8]. In all these
cases, it is crucial to promote proper homing of HSPCs and
thus ensure that as many CD34+ cells as possible home to the
BM and subsequently permanently engraft.
One of the major mechanisms that retains HSPCs in their
BM niches and directs their migration and homing from PB to
BM involves interaction of the CXCR4 receptor with α-
chemokine stromal-derived factor 1 (SDF-1). While CXCR4
is expressed on the surface of HSCs, SDF-1 is expressed on
the surface of cells lining the stem cell niches [1–3, 9]. Hom-
ing is also orchestrated by gradients of other chemotactic fac-
tors that show chemotactic activity against HSPCs. The list of
these chemoattractants is rather short, and so far it has been
demonstrated that, besides SDF-1, HSPCs respond to gradi-
ents of sphingosine-1-phosphate (S1P) [10–14], ceramide-1-
phosphate (C1P) [12], certain extracellular nucleotides, such
as ATP or UTP [15], as well as certain ions, such as Ca2+ and
H+ [16, 17].
In this review we present emerging strategies aimed at im-
proving the responsiveness of HSPCs to homing gradients as
well as strategies to increase the tethering of transplanted
HSPCs to the BM endothelium and subsequently their adhe-
sion in the BM microenvironment. In order to focus on this
particular topic, we will not discuss other strategies, such as
ex vivo expansion of HSPCs to be used in a graft or applica-
tion of allo-engraftment-facilitating cells. These strategies that
also lead to better engraftment of transplanted HSPCs were
recently reviewed elsewhere in excellent publications [18, 19].
Wewill review various strategies for improving the homing
and engraftment of HSPCs (Fig. 1), based on their classifica-
tion into the following categories: i) increasing the biological
effects of membrane lipid rafts, ii) modifying the expression
and function of BM homing molecules, iii) modifying the
metabolism of HSPCs, and iv) enhancing the availability of
chemotactic factors for HSPCs. However, we are aware that
this is a rather artificial classification of the strategies
employed in this review and is followed for reasons of sim-
plicity; however, several of these strategies, in fact, overlap
and involve more than one category.
Homing Strategies Based on Increasing
the Biological Effects of Membrane Lipid Rafts
The cell surface membrane is a selectively permeable structure
that separates the interior of the cell from the outside environ-
ment surrounding the cell. The cell membrane consists of a
phospholipid bilayer, with several embedded proteins, that is
held together via non-covalent interactions between the hy-
drophobic phospholipid tails. It has been demonstrated that,
under physiological conditions, phospholipid molecules in the
cell membrane are in a liquid crystalline state. However, cell
membranes also contain combinations of glycosphingolipids
and protein receptors organized into glycoprotein microdo-
mains, called lipid rafts, which play an important role in sev-
eral processes regulating cell biology [20, 21]. These dynamic
microscopic cholesterol-enriched structures are important in
assembling signaling molecules together with cell surface re-
ceptors and have been identified as playing a primary role in
signaling. For example, the SDF-1-binding, G protein-
coupled receptor CXCR4 must be incorporated into mem-
brane lipid rafts for optimal association with downstream sig-
naling proteins [22]. Thus, strategies aimed at promoting lipid
raft formation could enhance the responsiveness of HSPCs to
SDF-1 gradients and thereby facilitate homing of HSPCs
(Fig. 1a).
The Priming Effect of Certain Small Molecules That In-
crease the Responsiveness of HSCs to an SDF-1 Gradient
The SDF-1–CXCR4 axis is the most important chemotactic
axis involved in the homing of HSPCs to BM [1–3]. Never-
theless, the measured SDF-1 level in the BM microenviron-
ment after myeloblative conditioning for transplantation is
relatively low (2–3 ng/ml). This level is in striking contrast
to the SDF-1 doses usually employed (200–300 ng/ml) in
ex vivo experimental migration assays for HSPCs, which are
much too high and not physiologic. Moreover, although SDF-
1 mRNA increases in the BM microenvironment after
myeloablative conditioning by radio- or chemotherapy [23],
this treatment induces a highly proteolytic microenvironment
in BM [24]. SDF-1, as a peptide susceptible to proteolytic
digestion, is a target for several proteolytic enzymes that are
released from myeloid cells, and thus it becomes easily
digested and inactivated [25].
Nevertheless, evidence has accumulated that this potential
decrease in SDF-1 protein level in the BM microenvironment
after conditioning for transplantation is somewhat mitigated
by several factors, such as complement cascade (ComC)
cleavage fragments (C3a and desArgC3a), other cationic micro-
bial peptides released from granulocytes, such as cathelicidin
(LL-37) and β2-defensin, as well as other molecules, such as
hyaluronic acid, fibronectin, and soluble VCAM-1, ICAM-1,
and uPAR, which may significantly enhance the responsive-
ness of HSPCs to a shallow SDF-1 gradient [3, 21, 22, 26–28].
This phenomenon is known in the literature as a priming effect
on an SDF-1 gradient and significantly compensates for a
decrease in SDF-1 level in the BM microenvironment, which
occurs due to its degradation after induction of a proteolytic
microenvironment. The priming effect is explained by evi-
dence that all these small molecules promote lipid raft forma-
tion in HSPCs and thus increases HSPC responsiveness to an
SDF-1 gradient via recruitment of CXCR4 [29]. Therefore,
short ex vivo exposure of HSPCs to certain small molecules
before infusion enhances their homing to BM. This effect has
been demonstrated in vivo with C3a [30] and LL-37 [26].
Using several experimental strategies, including confocal
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microscopy and analysis of membrane fractions enriched in
lipid rafts, it has been demonstrated that, after exposure of
HSPCs to these small molecules, CXCR4 (a membrane lipid
raft-associated receptor) interacts more efficiently with SDF-1
and better engages proteins in downstream signaling path-
ways that are involved in trafficking and adhesion of HSPCs
[22, 31, 32].
The feasibility of ex vivo C3a priming of UCB cells before
infusion into the patient was recently demonstrated in a clin-
ical trial [33]. In the meantime, however, experimental evi-
dence has accumulated that LL-37, a cathelicidin fragment,
is a much more potent priming factor than C3a [26]. More-
over, since LL-37 is a physiological antibiotic peptide secreted
by granulocytes and a potentially safe molecule for ex vivo
graft manipulation, we propose an LL-37-based priming strat-
egy as an interesting and simple alternative.
Short Exposure ofHSPCs toMildHeat TreatmentAnother
interesting strategy to increase lipid raft formation on the sur-
face of HSPCs, and thus facilitate homing and engraftment of
these cells, has been proposed recently by another group [32].
Specifically, it was demonstrated that a short, mild ex vivo
heat treatment (39.5 °C) of a UCB graft primed the human
CD34+ cells for migration in response to an SDF-1 gradient
and enhanced engraftment of these cells in immunodeficient
mice.
This mild heat treatment was associated with increased
expression of CXCR4 on human CD34+ cells and, most im-
portantly, enhanced co-localization of CXCR4within the lipid
raft domains. CXCR4 incorporated in lipid rafts interacted
better with Rac-1, a GTPase that is crucial for cell migration
and adhesion [32]. Based on this intriguing observation, mild
heating of umbilical cord blood-derived HSPCs before trans-
plantation may, as proposed by the authors, become a relative-
ly simple and inexpensive strategy to enhance homing and
engraftment of transplanted cells.
Modification of Expression and Function of BM
Homing Molecules
There are several molecules on the surface of HSPCs that play
a role in directing cell migration in response to BM-released
chemoattractants, tethering of infused cells to the endothelium
in BM sinusoids, and promoting their subsequent adhesion in
the BMmicroenvironment. The most important receptors, be-
sides the already mentioned CXCR4, are the type 1 receptor
for S1P (S1PR1) and certain cell-surface mucins (e.g., P-
selectin glycoprotein ligand 1 [PSGL-1]) [34]. Based on these
findings, some of the strategies to improve homing have been
developed based, on the one hand, on increased expression of
these receptors on the cell surface and, on the other hand, on
enhancing their biological pro-adhesive functions (Fig. 1b).
Pulse Exposure of HSPCs to Prostaglandin E2 Prostaglan-
dins are very short-lived molecules that belong to a large fam-
ily of bioactive lipids. All nucleated cells, including those in
the BM microenvironment, synthesize prostaglandins, which
are involved in several pleiotropic biological effects. Prosta-
glandin E2 (PGE2) has been reported to be involved in regu-
lating the biology and trafficking of HSPCs [35]. It has been
shown that pulse exposure of murine or human BM cells to
PGE2 stimulates cell proliferation, cycling, and differentiation
of more primitive hematopoietic stem cells (HSCs), leading to
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an increase in the number of more differentiated hematopoi-
etic progenitor cells (HPCs) [35]. These observations obtained
with murine and human cells were recently validated in a
zebrafish model [36]. Based on these observations, a short-
pulse exposure to PGE2 was employed to facilitate engraft-
ment of murine and human HSPCs. As reported, one of the
effects of PGE2 is to increase expression of CXCR4 on the
surface of HSPCs, which facilitates their responsiveness to
SDF-1 gradients. Pre-clinical limiting-dilution studies re-
vealed that equivalent engraftment in immunodeficient mice
was achieved with 4-fold fewer PGE2-treated human UCB
cells than with untreated control UCB cells [37]. In sum, the
effect of PGE2 in upregulating CXCR4 receptor expression
plays an important role, on the one hand, in their migratory
responsiveness to an SDF-1 gradient and, on the other hand, in
tethering infused HSPCs to SDF-1 expressed on the surface of
endothelial cells in BM sinusoids [38]. This promising strate-
gy has already been confirmed in a clinical study and awaits
further validation [6].
Upregulation of the CXCR4 Receptor on the Surface of
HSPCs by Valporic Acid It is obvious that any strategy that
leads to upregulation of CXCR4 on the surface of HSPCs
would enhance the homing effect of the SDF-1–CXCR4 axis.
While potential application of CXCR4-overexpressing vec-
tors in HSPCs is problematic because of safety issues, a rela-
tively simple strategy has been proposed based on exposure of
HSPCs to the histone deacetylase inhibitor valporic acid
(VPA) [39]. It is well known that histone deacetylase inhibi-
tors, including VPA, stimulate proliferation and self-renewal
of normal HSPCs. Importantly, it has been demonstrated that
exposure of murine BM mononuclear cells to VPA enhanced
spleen colony formation and BM engraftment of murine
HSPCs. To shed more light on this phenomenon, human
UCB-derived CD34+ cells were exposed to VPA, and it has
been observed that such exposure both upregulates CXCR4
expression on the surface of HSPCs and enhances migration
of these cells up an SDF-1 gradient [39].
This relatively simple strategy to expose ex vivo HSPs to
VPA has become important, because VPA has recently been
successfully employed for expansion of UCB-derived primi-
tive HSCs, which are enriched for Oct-4+ cells [40]. There-
fore, the combined effects of VPA on upregulation of CXCR4
on the cell surface to enhance cell homing and on ex vivo
expansion of HSCs could become a promising strategy for
clinical application of this drug.
Surface Fucosylation of HSPCs As mentioned above, after
infusion into the circulation, HSPCs navigate towards the BM,
and the first step in the homing process is their rolling adhe-
sions and tethering on P-selectin and E-selectin, which are
expressed on the surface of endothelial cells in BM sinusoids
[34]. The P- and E-selectins expressed by endothelial cells are
membrane-bound lectins that interact with cell-surface
glycoconjugate ligands expressed on the surface of HSPCs.
In order to be biologically active, these selectin ligands have to
be properly α1-3 fucosylated [34].
The most important ligand for P- and E-selectins on endo-
thelial cells in BM sinusoids is the HSPC-expressed mucin
known as P-selectin glycoprotein ligand 1 (PSGL-1). It has
been reported in the case of UCB-derived HSPCs that α(1,3)
fucosylation of mucins on the surface of these cells is inade-
quate and results in poor binding of CD34+CD38–/low cells to
E- and P-selectins in BM sinusoids [34]. To ameliorate this
defect, UCB cells were exposed to guanosine diphosphate
fucose in the presence ofα(1,3) fucosyltransferase VI in order
to fucosylate cell surface mucins, including PSGL-1. It has
been reported that this ex vivo enzymatic approach enhanced
engraftment of UCB cells in BM in immunodeficient NOD/
SCID mice [34]. Nevertheless, this interesting strategy awaits
verification in a clinical setting.
BPainting^ of HSPCs by Platelet-Derived Extracellular
Microvesicles Another approach that has been proposed to
improve tethering of transplanted HSPCs to the BM endothe-
lium is ex vivo incubation of the HSPCs in a hematopoietic
graft with PB platelet-derived extracellular microvesicles
(ExMVs) [41]. It has been demonstrated that ExMVs transfer
not only CXCR4 but also several receptors that are crucial for
adhesion of platelets to endothelium from platelets to HSPCs.
Based on this effect, HSPCs isolated from murine BM or
human UCB and pre-incubated with platelet-derived ExMVs
engrafted much faster after transplantation into normal or
immundeficient mice, respectively [41]. Furthermore, since
HSPCs isolated frommobilized PB are already highly covered
by platelet-derived ExMVs as a result of platelet activation in
the plastic tubing during leucopheresis, this strategy is more
suitable for HSPCs aspirated from BM or isolated from UCB.
It has been hypothesized that, since HSPCs isolated from mo-
bilized PB are already densely covered by ExMVs, this phe-
nomenon may explain differences in engraftment kinetics be-
tween mPB-derived and BM-aspirated HSPCs.
Metabolic Modification of HSPCs
The knowledge and identification of metabolic pathways that
regulate self-renewal, proliferation, differentiation, and migra-
tion of HSPCs has increased significantly over the past few
years. In parallel, the role of mitochondria in HSPC biology as
a source of free radicals [42], the biological effects of heme
oxygenase 1 [43], and the involvement of glycogen synthase
kinase 3β (GSK-3β) as a regulator of the wingless (Wnt)–β
catenin pathway are better understood [44, 45]. Based on this
enhanced understanding, several new strategies to improve
homing and engraftment have been proposed (Fig. 1c).
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Exposure of Cells in Hematopoietic Grafts to Hypoxia as a
Means to Enhance Their Homing and Engraftment It is
known that HSPCs reside in specific BM stem cell niches
under hypoxic conditions and rely for their metabolism on
anaerobic glycolysis. As in BM, HSPCs in UCB are exposed
to hypoxia. By contrast, most of the current processing strat-
egies to prepare hematopoietic grafts from BM- or UCB-
derived cells are performed under hyperoxic conditions,
which leads to induction of transition pore permeability in
mitochondria and results in the release of free radicals or re-
active oxygen species (ROS) [42].
ROS, on the other hand, increase differentiation and cy-
cling of HSCs, which may result in their differentiation and
depletion. This effect of hyperoxia combined with release of
ROS from mitochondria has been named extraphysiologic
oxygen shock/stress (EPHOSS) [42]. This unwanted effect
of ROS release can be prevented by collection and processing
of HSPCs in low oxygen tension (3 %) in ambient air or in the
presence of cyclosporin A (CyA), which protects cells from
EPHOSS. In support of this concept, a beneficial effect of
hypoxia and CyAwas demonstrated in a recent elegant study
employing an HSPC transplant model in mice [42]. This
promising strategymay lead to initiation of a relatively simple,
but at the same time very promising, clinical trial to enhance
engraftment of UCB.
Inhibition of Heme Oxygenase 1 (HO-1) in HSPCs Heme
oxygenase 1 (HO-1) is an inducible stress-response enzyme
that not only catalyzes the degradation of heme (e.g., released
from damaged erythrocytes) but also performs an important
function in various physiological and pathophysiological
states associated with cellular stress, such as ischemic/
reperfusion injury. As already reported, HO-1 has negative
effects on adhesion and migration of neutrophils in the state
of acute inflammation [46], and this observation was con-
firmed recently for HSPCs [43]. HSPCs purified from HO-1
KO mice, and thus HO-1-deficient, show enhanced migration
in response to SDF-1 and S1P gradients. This phenomenon is
also supported by the highly migratory state in vivo of HSPCs
from mice lacking one HO-1 allele (HO-1+/−). Interestingly,
wild type mice transplanted with BM from HO-1+/− animals
showed accelerated hematopoietic recovery from myelotoxic
injury compared with lethally irradiated recipients
transplanted with BM cells from normal control animals
[43]. Unfortunately, mice transplanted with HO-1+/− HSPCs
were less effective in radioprotection as well as in serial re-
population studies of myeloablated recipients.
Based on these observations, we hypothesized that tran-
sient but not permanent inhibition of HO-1, achieved by
employing ex vivo exposure to small-molecule inhibitors of
this enzyme, could have a beneficial effect in increasing the
chemotactic responsiveness of HSPCs to SDF-1 and S1P
homing gradients and that this HO-1 transient inhibition
strategy could enhance homing and engraftment of
transplanted HSPCs [43]. In fact, our in vitro and in vivo
animal experiments demonstrated that transiently inhibiting
HO-1 activity in HSPCs by small-molecule inhibitors im-
proves HSPC homing and engraftment. We propose that this
simple and inexpensive strategy could be employed in the
clinical setting to improve engraftment of HSPCs, particularly
in those cases in which the number of HSPCs available for
transplant is limited and optimal engraftment of infused cells
is desirable.
Inhibition of GSK-3β in HSPCs to Improve Engraftment
The main purpose of hematopoietic transplantation is to trans-
plant long-term repopulating HSCs endowed with the ability
to sustain long-term hematopoiesis. Glycogen synthase kinase
3β (GSK-3β) has been identified as an important regulator of
HSC function due to activation of the wingless (Wnt)–β-ca-
tenin pathway, which stimulates proliferation of HSCs [44].
Thus, Wnt–β catenin signaling plays an important role in
maintaining stem cell regenerative potential under steady-
state conditions. Wnt signaling enforces quiescence of HSCs
in BM niches and preserves the capacity of these cells for self-
renewal. This mechanism is often perturbed in cells isolated
from BM or UCB and, in particular, in HSPCs after their
ex vivo expansion. Therefore, a novel strategy based on
ex vivo applicat ion of the GSK-3β inhibitor, 6-
bromoindirubin 3′ oxime (BIO), has been proposed to delay
cycling of harvested cells so that long-term repopulating
HSCs will be preserved in the graft [45]. In appropriate exper-
imental models it has been convincingly demonstrated that
GSK-3β inhibition promotes engraftment of ex vivo-
expanded human and murine HSPCs in normal and immuno-
deficient mouse models, respectively [44, 45]. However, this
strategy of employing a small-molecule inhibitor of GSK-3β
has not yet been tested in a clinical setting.
Enhancing the Availability of Chemotactic Factors
for HSPCs
HSPC chemotactic factors play a crucial role in BM homing
and, as mentioned above, a proteolytic microenvironment in-
duced by myeloablative conditioning affects the bioavailabil-
ity of SDF-1 in BM.While we have learned a lot about induc-
tion of a proteolytic microenvironment in BM as a response to
myeloablative conditioning, more work is needed to see
whether, in addition to proteolytic enzymes, lipolytic enzymes
are also induced and thereby affect the bioavailability of S1P
and C1P. Similarly, enzymes degrading ATP could also poten-
tially affect an ATP homing gradient. On the other hand, as
will be discussed below, some of the enzymes that may affect
the bioavailability of chemotactic factors are secreted by
HSPCs themselves (Fig. 1d).
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Inhibition of Dipeptidylpeptidase 4 (DPP4) on the Surface
of HSPCs Dipeptidylpeptidase 4 (DPP4, also known as
CD26) antigen, expressed on the surface of HSPCs, is
endowed with proteolytic activity and may inactivate SDF-1
close to the cell membrane before it engages the CXCR4
receptor [47]. To ameliorate this unwanted effect, it has been
proposed that blockade of DPP4 enhances the responsiveness
of HSPCs to an SDF-1 gradient. In support of this hypothesis,
both competitive and non-competitive hematopoietic trans-
plants of murine and human HSPCs in normal and immuno-
deficient mice, respectively, revealed that a short exposure of
transplanted cells to diprotinin A, which is an inhibitor of
proteolytic DPP4 activity on the cell surface, enhanced hom-
ing and engraftment of these cells [47]. Thus, inhibition of
DPP4 prevents SDF-1 degradation and facilitates its chemo-
tactic interaction with the CXCR4 receptor. Most importantly,
an oral inhibitor of DPP4 known as sitagliptin has been de-
veloped, and this form of DPP4 inhibitor is currently
employed in clinical trials in humans transplanted with UCB
[6]. This promising strategy awaits clinical verification with a
larger number of patients.
Modification of the Responsiveness of HSPCs to S1P and
C1P Gradients As ment ioned above, b ioac t ive
phosphosphingolipids are potent chemoattractants for HSPCs
in physiological doses and the cell-surface binding receptors
for S1P are well described. These receptors are members of a
family of five receptors (S1PR1–S1PR5), of which S1PR1 is
crucial in eliciting the chemotactic responsiveness of cells to
an S1P gradient [29]. By contrast, S1PR2 has the opposite
function [29]. Therefore, one tempting strategy is to blockade
S1PR2 by employing a specific small-molecule inhibitor, JTE-
013. This strategy has already been demonstrated to improve
migration of neural progenitors in response to an S1P gradient
[48].
HSPCs also express lipid phosphate phosphatases (LPP1–
3) on the cell surface, which possess ecto-enzymatic-
degrading activity against S1P and C1P [29, 49]. Thus,
LPP1–3 expressed on the surface of HSPCs could negatively
affect their migration in response to gradients of C1P and S1P
(dephosphorylated sphingosine and ceramide do not
chemoattract HSPCs). This is a somewhat analogous phenom-
enon to the effect of DPP4 on SDF-1-mediated chemotaxis.
Therefore, in order to increase the responsiveness of HSPCs to
S1P and C1P gradients, it would be interesting to see whether
ex vivo exposure of HSPCs to the LLP inhibitor XY-14 en-
hances engraftment of HSPCs.
Finally, since the BM level of S1P may be additionally
increased by inhibiting S1P lyase (SPL) by deoxypyridoxine
(DOP), a vitamin B6 antagonist , or 2-acethyl-4-
tertrahydroxybutylimaidazole (THI), this inhibition should
enhance the S1P level in BM and thus additionally improve
the responsiveness of HSPCs to an S1P homing gradient [29].
Since inhibitors of S1P lyase (DOP and THI) are FDA-
approved compounds, this relatively simple strategy for im-
proving homing of HSPCs in patients that can be
preconditioned before transplantation with an SPL inhibitor
awaits experimental verification.
Conclusions
Optimal and efficient stem cell homing will also enable
achievement of the desired therapeutic effect using a lower
number of stem cells. This is important, for example, in trans-
plantation of UCB. Since the number of HSCs in UCB is
limited and often insufficient to transplant to an adult recipi-
ent, strategies that enhance homing (seeding efficiency of
HSCs to BM) and subsequent engraftment of UCB-derived
HSCs are vital for positive clinical outcomes. In the near fu-
ture we expect that some of the strategies proposed above will
be widely employed or that even more novel and powerful
strategies will be developed to enhance stem cell homing that
target both the local niche and the stem cells employed for
treatment. In addition, it is also possible to combine some of
the strategies for improved homing, as discussed above. In
support of this notion, inhibition of DPP4 was successfully
combined with a short exposure of human or murine HSPCs
to PGE2 to enhance their engraftment in experimental animal
models [38]. Moreover new factors become identified such as
for example DEK protein [50] that may ex vivo stimulate
hematopoietic graft and thus enhance homing and engraft-
ment of HSPCs. Finally, efficient homing and engraftment
of stem cells employed in therapy has an immediate impact
on the final outcome of the therapy not only in hematological
settings but also in other potential applications of stem cells in
tissue or organ injuries (e.g., to myocardium, liver, or kidney)
[51].
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